Recombinant Anti-Fragilis antibody [EPR5242] (ab109429)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR5242] to Fragilis
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Fragilis antibody [EPR5242]
See all Fragilis primary antibodies -
Description
Rabbit monoclonal [EPR5242] to Fragilis -
Host species
Rabbit -
Specificity
Predicted cross-reactivity with IFITM2 (93% homology) but this has not been tested.
-
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt or IP -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: HeLa whole cell lysate (PMID: 21177806), Recombinant Human Fragilis protein. IHC-P: Human kidney tissue. This antibody gave a positive result when used in the following formaldehyde fixed cell lines: HeLa.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR5242 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab109429 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 15 kDa.
|
|
IHC-P |
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Antigen retrieval is recommended. |
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 15 kDa. |
IHC-P
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. Antigen retrieval is recommended. |
Target
-
Function
IFN-induced antiviral protein that mediates cellular innate immunity to at least three major human pathogens, namely influenza A H1N1 virus, West Nile virus (WNV), and dengue virus (WNV), by inhibiting the early step(s) of replication. -
Sequence similarities
Belongs to the CD225 family. -
Post-translational
modificationsPalmitoylation on membrane-proximal cysteines controls clustering in membrane compartments and antiviral activity against influenza virus. -
Cellular localization
Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 10410 Human
- Omim: 605579 Human
- SwissProt: Q01628 Human
- Unigene: 374650 Human
-
Alternative names
- 1 8U antibody
- Fragilis antibody
- IFITM3 antibody
see all
Images
-
All lanes : Anti-Fragilis antibody [EPR5242] (ab109429) at 1/1000 dilution
Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate
Lane 2 : 293T (Human embryonic kidney epithelial cell) whole cell lysate
Lane 3 : HAP1 (Human chronic myelogenous leukemia near-haploid cell line) whole cell lysate
Lane 4 : Jurkat (Human T cell leukemia T lymphocyte) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 15 kDa
Observed band size: 15 kDa
Exposure time: 1 secondLane 1: Positive control - Hela (PMID: 21177806)
Lanes 2-4: Negative control - 293T and Jurkat (PMID: 21177806) HAP1(PMID: 29079573).
Blocking buffer: 5% NFDM/TBST
-
Immunohistochemical analysis of Fragilis in paraffin-embedded Human kidney tissue using ab109429 at 1/250 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Anti-Fragilis antibody [EPR5242] (ab109429) at 1/1000 dilution +
Recombinant Human Fragilis protein (ab92921) at 0.01 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 15 kDa
Exposure time: 10 seconds
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (16)
ab109429 has been referenced in 16 publications.
- Shi G et al. Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. bioRxiv N/A:N/A (2021). PubMed: 33880473
- Cai Y et al. Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors. Front Immunol 12:704965 (2021). PubMed: 34456915
- Liu W et al. TUG1 promotes the expression of IFITM3 in hepatocellular carcinoma by competitively binding to miR-29a. J Cancer 12:6905-6920 (2021). PubMed: 34659578
- Ahi YS et al. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag. mBio 11:N/A (2020). PubMed: 31964738
- Zhu X et al. miR-152-3p Affects the Progression of Colon Cancer via the KLF4/IFITM3 Axis. Comput Math Methods Med 2020:8209504 (2020). PubMed: 32952601